VolitionRx Limited reported its financial results for the first quarter of 2026, revealing total revenues of $985,076, a significant increase from $246,385 in the same period of 2025. This growth was primarily driven by a substantial rise in product revenues, which surged to $926,127 from $130,909 year-over-year, largely attributed to the recognition of deferred revenue related to the Nu.Q® Vet Cancer Test. However, service revenues declined by 49% to $58,949, reflecting a shift in focus towards product sales.
The company's operating expenses also increased, totaling $6.3 million for the quarter, compared to $5.8 million in the prior year. This rise was influenced by higher research and development costs, which grew to $2.9 million, primarily due to ongoing clinical trials for lung cancer studies. General and administrative expenses rose by 17% to $2.6 million, driven by increased legal and professional fees. Despite these higher expenses, VolitionRx reported a reduced operating loss of $5.3 million, down from $5.5 million in the previous year.
In terms of strategic developments, VolitionRx has been actively expanding its product offerings and market presence. The company has entered into various licensing agreements, including partnerships with established diagnostic firms such as Werfen and Hologic, aimed at enhancing the commercialization of its Nu.Q® product line. Additionally, the Nu.Q® Vet Cancer Test has been launched in multiple countries, including the UK, Ireland, and Japan, further broadening its market reach.
As of March 31, 2026, VolitionRx had cash and cash equivalents of approximately $3.1 million, an increase from $1.1 million at the end of 2025. The company utilized $5.3 million in cash for operating activities during the quarter, reflecting a rise in expenditures associated with clinical trials. The firm continues to face challenges in achieving profitability, with an accumulated deficit of $259.6 million. Management has indicated that future operations will depend on securing additional capital through equity or debt financing, as well as generating revenue from its product lines.
Looking ahead, VolitionRx remains focused on advancing its clinical-stage diagnostic tests and expanding its market presence. The company is actively pursuing additional financing options and exploring strategic partnerships to support its growth initiatives. However, the ongoing need for funding raises concerns about the company's ability to continue as a going concern without further financial support.
About VOLITIONRX LTD
VolitionRx Limited is a multinational epigenetics company developing simple, cost-effective blood tests for early detection and monitoring of diseases such as cancer and sepsis in humans and animals. Its proprietary technologies analyze circulating nucleosomes and chromatin structures to enable non-invasive diagnostics, with applications spanning veterinary and human healthcare markets. The company focuses on innovative assay development, licensing IP, and strategic partnerships to improve disease management worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.